

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1615

Kitaoka, Kenichi et al.

Examiner: Ahmed, Hasan Syed

INTERNATIONAL APPLICATION NO: PCT/EP2004/006865

FILED: June 24, 2004

U.S. APPLICATION NO: 10/560940

35 USC §371 DATE: December 15, 2005

FOR: Tablet Comprising Fluvastatin and Carmellose Calcium

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Jennifer Q. Chapman
Attorney for Applicant
Reg. No. 47,487

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-1202

Date:

July 7, 2009